Investor Presentaiton

Strong Q3 in Continence Care with 9% growth. Solid contribution across product groups, incl. Collecting Devices, following backorder resolution Continence Care performance 11 9 LO 00 8 7 5 9 5 2,030 1,987 1,892 1,964 1,993 • Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Revenues (DKKm) Organic growth (%) Q3 22/23 Reported growth (%) • Q3 2022/23 highlights Solid contribution to growth from all regions • Continued good sales momentum in the US and Europe, led by France Emerging markets growth driven by LATAM Continued double-digit growth in markets with recent reimbursement openings, such as Poland, Australia, Japan and South Korea From a product perspective, the SpeediCathⓇ intermittent catheters portfolio, in particular compact, standard, and flexible catheters, were the main contributors to growth Bowel Management continued to contribute nicely to growth, driven by PeristeenⓇ Plus in the US and Europe Collecting Devices also delivered a solid quarter, as expected, following the resolution of the backorder situation Launch of Luja™, the new male intermittent catheter with a Micro-hole Zone Technology, is ongoing, with positive feedback from users and clinicians. Launch in key markets is expected over the next 6 months Coloplast has presented the results of its second pivotal clinical study on Luja, confirming the improved performance of Luja seen in the first pivotal study 7 Luja is a medical device for which CE-mark has been affixed. Product availability is subject to regulatory process of individual countries and is not guaranteed Coloplast

View entire presentation